Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
272 hedge funds and large institutions have $7.01B invested in Avidity Biosciences in 2025 Q3 according to their latest regulatory filings, with 84 funds opening new positions, 113 increasing their positions, 57 reducing their positions, and 14 closing their positions.
500% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 14
139% more call options, than puts
Call options by funds: $64.1M | Put options by funds: $26.9M
98% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 57
82% more capital invested
Capital invested by funds: $3.86B → $7.01B (+$3.15B)
32% more funds holding
Funds holding: 206 → 272 (+66)
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
2.5% less ownership
Funds ownership: 112.82% → 110.32% (-2.5%)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$218M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$161M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$151M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$87M |
| 5 |
RI
RTW Investments
New York
|
+$70.9M |
Top Sellers
RNAM Hedge Fund Activity: Q3 2025 in Review
272 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q3 2025, worth a combined $7.01B — up 82% from $3.86B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new RNAM positions and 14 closed out — a net gain of 70 holders — while 113 added to existing stakes and 57 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $218M. The largest seller was Toronto Dominion Bank, exiting entirely with an estimated $100M sold.
- 272 institutional investors held Avidity Biosciences (RNAM) as of Q3 2025, up from 206 in Q2 2025.
- Funds reported $7.01B of Avidity Biosciences stock for Q3 2025, up 82% quarter-over-quarter.
- 84 funds opened new Avidity Biosciences positions in Q3 2025 and 14 closed out, a net change of +70 holders.
- The largest Avidity Biosciences buyer in Q3 2025 was Fidelity Investments, an estimated $218M added.
- The largest Avidity Biosciences seller in Q3 2025 was Toronto Dominion Bank, an estimated $100M sold.
Based on aggregated 13F filings for Q3 2025.